» Articles » PMID: 28179361

A Microbial Signature for Crohn's Disease

Abstract

Objective: A decade of microbiome studies has linked IBD to an alteration in the gut microbial community of genetically predisposed subjects. However, existing profiles of gut microbiome dysbiosis in adult IBD patients are inconsistent among published studies, and did not allow the identification of microbial signatures for CD and UC. Here, we aimed to compare the faecal microbiome of CD with patients having UC and with non-IBD subjects in a longitudinal study.

Design: We analysed a cohort of 2045 non-IBD and IBD faecal samples from four countries (Spain, Belgium, the UK and Germany), applied a 16S rRNA sequencing approach and analysed a total dataset of 115 million sequences.

Results: In the Spanish cohort, dysbiosis was found significantly greater in patients with CD than with UC, as shown by a more reduced diversity, a less stable microbial community and eight microbial groups were proposed as a specific microbial signature for CD. Tested against the whole cohort, the signature achieved an overall sensitivity of 80% and a specificity of 94%, 94%, 89% and 91% for the detection of CD versus healthy controls, patients with anorexia, IBS and UC, respectively.

Conclusions: Although UC and CD share many epidemiologic, immunologic, therapeutic and clinical features, our results showed that they are two distinct subtypes of IBD at the microbiome level. For the first time, we are proposing microbiomarkers to discriminate between CD and non-CD independently of geographical regions.

Citing Articles

Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities.

Iliev I, Ananthakrishnan A, Guo C Nat Rev Microbiol. 2025; .

PMID: 40065181 DOI: 10.1038/s41579-025-01163-0.


Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease.

Su F, Su M, Wei W, Wu J, Chen L, Sun X Gut Microbes. 2025; 17(1):2476570.

PMID: 40063366 PMC: 11901428. DOI: 10.1080/19490976.2025.2476570.


Gut microbiota dysfunction in Crohn's disease.

Buffet-Bataillon S, Durao G, Le Huerou-Luron I, Rue O, Le Cunff Y, Cattoir V Front Cell Infect Microbiol. 2025; 15:1540352.

PMID: 40007605 PMC: 11850416. DOI: 10.3389/fcimb.2025.1540352.


Oral Microbiota and Inflammatory Bowel Diseases: Detection of Emerging Fungal Pathogens and Herpesvirus.

Oliveira M, Campos L, Brito F, de Carvalho F, Silva-Junior G, da Costa G Biomedicines. 2025; 13(2).

PMID: 40002893 PMC: 11852465. DOI: 10.3390/biomedicines13020480.


Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases.

Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M Biomedicines. 2025; 13(2).

PMID: 40002718 PMC: 11853239. DOI: 10.3390/biomedicines13020305.


References
1.
Goodrich J, Waters J, Poole A, Sutter J, Koren O, Blekhman R . Human genetics shape the gut microbiome. Cell. 2014; 159(4):789-99. PMC: 4255478. DOI: 10.1016/j.cell.2014.09.053. View

2.
Navas-Molina J, Peralta-Sanchez J, Gonzalez A, McMurdie P, Vazquez-Baeza Y, Xu Z . Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 2013; 531:371-444. PMC: 4517945. DOI: 10.1016/B978-0-12-407863-5.00019-8. View

3.
Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J . Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015; 5:12693. PMC: 4523847. DOI: 10.1038/srep12693. View

4.
Thomas G, Rhodes J, Green J, Richardson C . Role of smoking in inflammatory bowel disease: implications for therapy. Postgrad Med J. 2000; 76(895):273-9. PMC: 1741576. DOI: 10.1136/pmj.76.895.273. View

5.
Huggan P, Murdoch D . Fusobacterial infections: clinical spectrum and incidence of invasive disease. J Infect. 2008; 57(4):283-9. DOI: 10.1016/j.jinf.2008.07.016. View